Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver

Inflammation and metabolic disorders

Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199 · see citing works

FGF-21 as a novel metabolic regulator

Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125 · see citing works

Endocrine Regulation of the Fasting Response by PPARα-Mediated Induction of Fibroblast Growth Factor 21

Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504 · see citing works

Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression

Schoonjans, K., Staels, B., & Auwerx, J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42003-6 · Cited by 1,216 · see citing works

A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport

Oliver, W. R., Shenk, J. L., Snaith, M. R., RUSSELL, C. S., Plunket, K. D., Bodkin, N. L., Lewis, M. C., Winegar, D. A., Sznaidman, M. L., Lambert, M. H., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091021198 · Cited by 1,048 · see citing works

International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors

Michalik, L., Auwerx, J. H., Berger, J. P., Chatterjee, K., Glass, C. K., Gonzalez, F. J., Grimaldi, P. A., Kadowaki, T., Lazar, M. A., O’Rahilly, S., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.5 · Cited by 997 · see citing works

Sorting out the roles of PPAR  in energy metabolism and vascular homeostasis

Lefebvre, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27989 · Cited by 962 · see citing works

Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome

Tanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R. X., Tachibana, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306981100 · Cited by 832 · see citing works

Endoplasmic Reticulum Stress Activates Cleavage of CREBH to Induce a Systemic Inflammatory Response

Zhang, K., Shen, X., Wu, J., Sakaki, K., Saunders, T. L., Rutkowski, D. T., Back, S. H., & Kaufman, R. J. (2006) · Cell · doi:10.1016/j.cell.2005.11.040 · Cited by 819 · see citing works

Integrated physiology and systems biology of PPARα

Kersten, S. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.02.002 · Cited by 679 · see citing works

PHASE II DRUG METABOLIZING ENZYMES

Jancova, P., Anzenbacher, P., & Anzenbacherová, E. (2010) · Biomedical Papers · doi:10.5507/bp.2010.017 · Cited by 611 · see citing works

Peroxisome biogenesis disorders

Steinberg, S. J., Dodt, G., Raymond, G. V., Braverman, N. E., Moser, A. B., & Moser, H. W. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.09.010 · Cited by 522 · see citing works

Peroxisome proliferator activated receptor-alpha expression in human liver.

Palmer, C. N., Hsu, M. H., Griffin, K. J., Raucy, J. L., & Johnson, E. F. (1998) · PubMed · Cited by 448 · see citing works

Mannose‐binding lectin and innate immunity

Ip, W., Takahashi, K., Ezekowitz, R. A. B., & Stuart, L. M. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00789.x · Cited by 418 · see citing works

Peroxisome Proliferator Activated Receptor-α Expression in Human Liver

Palmer, C. N. A., Hsu, M.-H., Griffin, K. J., Raucy, J. L., & Johnson, E. F. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.1.14 · Cited by 416 · see citing works

Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids.

Rodríguez, J. C., Gil‐Gómez, G., Hegardt, F. G., & Haro, D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32234-2 · Cited by 378 · see citing works

PPARα is a key regulator of hepatic FGF21

Lundåsen, T., Hunt, M., Nilsson, L.-M., Sanyal, S., Angelin, B., Alexson, S., & Rudling, M. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.06.068 · Cited by 361 · see citing works

PPARα: Mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators

Gonzalez, F. J., & Shah, Y. M. (2007) · Toxicology · doi:10.1016/j.tox.2007.09.030 · Cited by 262 · see citing works

Regulation of Pyruvate Dehydrogenase Kinase Expression by Peroxisome Proliferator–Activated Receptor-α Ligands, Glucocorticoids, and Insulin

Huang, B., Wu, P., Bowker-Kinley, M. M., & Harris, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.2.276 · Cited by 246 · see citing works

Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease

Fruchart, J.-C. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.008 · Cited by 233 · see citing works

Adaptive Increase in Pyruvate Dehydrogenase Kinase 4 during Starvation Is Mediated by Peroxisome Proliferator-Activated Receptor α

Wu, P., Peters, J. M., & Harris, R. A. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5608 · Cited by 206 · see citing works

Endoplasmic reticulum-tethered transcription factor cAMP responsive element-binding protein, hepatocyte specific, regulates hepatic lipogenesis, fatty acid oxidation, and lipolysis upon metabolic stress in mice

Zhang, C., Wang, G., Zheng, Z., Maddipati, K. R., Zhang, X., Dyson, G. E., Williams, P., Duncan, S. A., Kaufman, R. J., & Zhang, K. (2011) · Hepatology · doi:10.1002/hep.24783 · Cited by 194 · see citing works

Regulation of Hepatic Gluconeogenesis by an ER-Bound Transcription Factor, CREBH

Lee, M., Chanda, D., Yang, J., Oh, H., Kim, S. S., Yoon, Y.-S., Hong, S., Park, K., Lee, I., Choi, C. S., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.02.016 · Cited by 194 · see citing works

Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists

Fruchart, J.-C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-82 · Cited by 189 · see citing works

CREB-H: a novel mammalian transcription factor belonging to the CREB/ATF family and functioning via the box-B element with a liver-specific expression

Omori, Y. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.10.2154 · Cited by 167 · see citing works

A Novel Member of Solute Carrier Family 25 (SLC25A42) Is a Transporter of Coenzyme A and Adenosine 3′,5′-Diphosphate in Human Mitochondria

Fiermonte, G., Paradies, E., Todisco, S., Marobbio, C. M. T., & Palmieri, F. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.014118 · Cited by 161 · see citing works

ATP-Binding Membrane Cassette Transporter A1 (ABCA1): A Possible Link between Inflammation and Reverse Cholesterol Transport

Yin, K., Liao, D., & Tang, C. (2010) · Molecular Medicine · doi:10.2119/molmed.2010.00004 · Cited by 152 · see citing works

Long-Acting FGF21 Has Enhanced Efficacy in Diet-Induced Obese Mice and in Obese Rhesus Monkeys

Véniant, M. M., Komorowski, R., Chen, P., Stanislaus, S., Winters, K., Hager, T., Zhou, L., Wada, R., Hecht, R. I., & Xu, J. (2012) · Endocrinology · doi:10.1210/en.2012-1211 · Cited by 147 · see citing works

Transactivation of the PPAR-Responsive Enhancer Module in Chemopreventive Glutathione S -Transferase Gene by the Peroxisome Proliferator-Activated Receptor-γ and Retinoid X Receptor Heterodimer

Park, E. Y., Cho, I. J., & Kim, S. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3924 · Cited by 138 · see citing works

Human HMGCS2 Regulates Mitochondrial Fatty Acid Oxidation and FGF21 Expression in HepG2 Cell Line

Vilà-Brau, A., Sousa‐Coelho, A. L. D., Mayordomo, C., Haro, D., & Marrero, P. F. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.235044 · Cited by 137 · see citing works

Liver-Enriched Transcription Factor CREBH Interacts With Peroxisome Proliferator-Activated Receptor α to Regulate Metabolic Hormone FGF21

Kim, H., Méndez, R., Zheng, Z., Chang, L., Cai, J., Zhang, R., & Zhang, K. (2014) · Endocrinology · doi:10.1210/en.2013-1490 · Cited by 134 · see citing works

Characterization and tissue-specific expression of the human ‘very low density lipoprotein (VLDL) receptor’ mRNA

Webb, J. C., Patel, D. D., Jones, M. D., Knight, B. L., & Soutar, A. K. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.4.531 · Cited by 133 · see citing works

PPARα activators and fasting induce the expression of adipose differentiation-related protein in liver

Dalen, K. T., Ulven, S. M., Arntsen, B. M., Solaas, K., & Nebb, H. I. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m500459-jlr200 · Cited by 126 · see citing works

Peroxisome Proliferator-induced Long Chain Acyl-CoA Thioesterases Comprise a Highly Conserved Novel Multi-gene Family Involved in Lipid Metabolism

Hunt, M. C., Nousiainen, S. E. B., Huttunen, M., Orii, K. E., Svensson, T., & Alexson, S. E. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.48.34317 · Cited by 106 · see citing works

PPAR-alpha dependent regulation of vanin-1 mediates hepatic lipid metabolism

van Diepen, J. A., Jansen, P. A. M., Ballak, D. B., Hijmans, A., Hooiveld, G. J. E. J., Rommelaere, S., Galland, F., Naquet, P., Rutjes, F. P. J. T., Mensink, R. P., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.04.013 · Cited by 92 · see citing works

Regulation of peroxisomal lipid metabolism: The role of acyl-CoA and coenzyme A metabolizing enzymes

Hunt, M. C., Tillander, V., & Alexson, S. E. H. (2014) · Biochimie · doi:10.1016/j.biochi.2013.12.018 · Cited by 87 · see citing works

Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor α agonists

Yamazaki, Y., Abe, K., Toma, T., Nishikawa, M., Ozawa, H., Okuda, A., Araki, T., Oda, S., Inoue, K., Shibuya, K., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.066 · Cited by 84 · see citing works

The acyl-CoA thioesterase I is regulated by PPARα and HNF4α via a distal response element in the promoter

Dongol, B., Shah, Y. M., Kim, I., Gonzalez, F. J., & Hunt, M. C. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700119-jlr200 · Cited by 82 · see citing works

Induction of the Fatty Acid Transport Protein 1 and Acyl-CoA Synthase Genes by Dimer-selective Rexinoids Suggests That the Peroxisome Proliferator-activated Receptor-Retinoid X Receptor Heterodimer Is Their Molecular Target

Martin, G., Poirier, H., Crombie, D. L., Fruchart, J., Heyman, R. A., Besnard, P., Auwerx, J. H., & Hennuyer, N. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.17.12612 · Cited by 78 · see citing works

Transcriptional activation of Cidec by PPARγ2 in adipocyte

Kim, Y.-J., Cho, S. Y., Yun, C. H., Moon, Y. S., Lee, T. R., & Kim, S. H. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.09.129 · Cited by 72 · see citing works

PPARgamma activators stimulate aquaporin 3 expression in keratinocytes/epidermis

Jiang, Y. J., Kim, P., Lu, Y. F., & Feingold, K. R. (2011) · Experimental Dermatology · doi:10.1111/j.1600-0625.2011.01269.x · Cited by 71 · see citing works

The liver-enriched transcription factor CREBH is nutritionally regulated and activated by fatty acids and PPARα

Danno, H., Ishii, K., Nakagawa, Y., Mikami, M., Yamamoto, T., Yabe, S., Furusawa, M., Kumadaki, S., Watanabe, K., Shimizu, H., et al. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.046 · Cited by 70 · see citing works

Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology

Li, H., Zhang, J., & Jia, W. (2013) · Frontiers of Medicine · doi:10.1007/s11684-013-0244-8 · Cited by 69 · see citing works

Characterization of the Species-Specificity of Peroxisome Proliferators in Rat and Human Hepatocytes

Ammerschlaeger, M. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh071 · Cited by 69 · see citing works

PPARalpha regulates the production of serum Vanin‐1 by liver

Rommelaere, S., Millet, V., Gensollen, T., Bourges, C., Eeckhoute, J., Hennuyer, N., Baugé, E., Chasson, L., Cacciatore, I., Staels, B., et al. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.09.046 · Cited by 69 · see citing works

Mannose-Binding Lectin Gene Polymorphisms Are Associated with Gestational Diabetes Mellitus

Megía, A., Gallart, L., Fernández‐Real, J. M., Vendrell, J. J., Simón, I., Gutiérrez, C., & Richart, C. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0211 · Cited by 58 · see citing works

Upregulation of hepatic VLDLR via PPARα is required for the triglyceride-lowering effect of fenofibrate

Gao, Y., Shen, W., Lu, B., Zhang, Q., Hu, Y., & Chen, Y. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m041988 · Cited by 56 · see citing works

Hypertension and Angiotensin II Hypersensitivity in Aminopeptidase A—deficient Mice

Mitsui, T., Nomura, S., Okada, M., Ohno, Y., Kobayashi, H., Nakashima, Y., Murata, Y., Takeuchi, M., Kuno, N., Nagasaka, T., et al. (2003) · Molecular Medicine · doi:10.1007/bf03402108 · Cited by 56 · see citing works

Possible involvement of oxidative stress in fenofibrate-induced hepatocarcinogenesis in rats

Nishimura, J., Dewa, Y., Okamura, T., Muguruma, M., Jin, M., Saegusa, Y., Umemura, T., & Mitsumori, K. (2008) · Archives of Toxicology · doi:10.1007/s00204-007-0278-2 · Cited by 49 · see citing works

New insights into the importance of aminopeptidase A in hypertension

Mizutani, S., Ishii, M., Hattori, A., Nomura, S., Numaguchi, Y., Tsujimoto, M., Kobayshi, H., Murohara, T., & Wright, J. W. (2007) · Heart Failure Reviews · doi:10.1007/s10741-007-9065-7 · Cited by 44 · see citing works

Arylacetamide deacetylase: A novel host factor with important roles in the lipolysis of cellular triacylglycerol stores, VLDL assembly and HCV production

Nourbakhsh, M., Douglas, D. N., Pu, C. H., Lewis, J. T., Kawahara, T., Lisboa, L. F., Wei, E., Asthana, S., Quiroga, A. D., Law, L. M. J., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.022 · Cited by 35 · see citing works

5-Aminoimidazole-4-carboxyamide-ribonucleoside (AICAR)-Stimulated Hepatic Expression of Cyp4a10, Cyp4a14, Cyp4a31, and Other Peroxisome Proliferator-Activated Receptor α-Responsive Mouse Genes Is AICAR 5′-Monophosphate-Dependent and AMP-Activated Protein Kinase-Independent

Bumpus, N. N., & Johnson, E. F. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.184242 · Cited by 33 · see citing works

PPARβ/δ activation of CD300a controls intestinal immunity

Tanaka, T., Tahara‐Hanaoka, S., Nabekura, T., Ikeda, K., Jiang, S. S., Tsutsumi, S., Inagaki, T., Magoori, K., Higurashi, T., Takahashi, H., et al. (2014) · Scientific Reports · doi:10.1038/srep05412 · Cited by 31 · see citing works

ATP-binding cassette transporter A1: key player in cardiovascular and metabolic disease at local and systemic level

van Eck, M. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000088 · Cited by 25 · see citing works

Proteomics analysis of cardiac muscle from rats with peroxisomal proliferator-activated receptor .ALPHA. (PPAR.ALPHA.) stimulation

Miyazaki, M., Nakagawa, I., Koga, S., Kasahara, Y., & Patricelli, M. P. (2010) · The Journal of Toxicological Sciences · doi:10.2131/jts.35.131 · Cited by 16 · see citing works

Fibrates after the FIELD study: some answers, more questions

Wierzbicki, A. (2006) · Diabetes & vascular disease research · doi:10.3132/dvdr.2006.025 · Cited by 14 · see citing works

High Density Lipoprotein Turnover is Dependent on Peroxisome Proliferator-Activated Receptor α in Mice

Akita, N., Tsujita, M., Yokota, T., Gonzalez, F. J., Ohte, N., Kimura, G., & Yokoyama, S. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.4820 · Cited by 7 · see citing works

Acyl-CoA Thioesterases Belong to a Novel Gene Family of Peroxisome Proliferator-Regulated Enzymes Involved in Lipid Metabolism

Hunt, M. C., Lindquist, P. J. G., Nousiainen, S. E. B., Huttunen, M., Orii, K. E., Svensson, T., Aoyama, T., Hashimoto, T., Diczfalusy, U., & Alexson, S. E. H. (2000) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:32:1-3:317 · Cited by 6 · see citing works

Abstract 17336: Marked Increase of Plasma Fibroblast Growth Factor 21 in Dyslipidemic Patients Treated With K-877, a Novel Highly Potent and Specific Peroxisome Proliferator-Activated Receptor Alpha Agonist

Yokote, K., Ishibashi, S., Yamashita, S., Arai, H., Araki, E., & Kodama, T. (2013) · Circulation · Cited by 2 · see citing works

PPAR Agonists and Metabolic Syndrome: An Established Role?

Botta, M., Audano, M., Sahebkar, A., Sirtori, C. R., Mitro, N., & Ruscica, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041197 · Cited by 253 · see citing works

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

Ishibashi, S., Yamashita, S., Arai, H., Araki, E., Yokote, K., Suganami, H., Fruchart, J.-C., & Kodama, T. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.029 · Cited by 208 · see citing works

Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases

Yamashita, S., Masuda, D., & Matsuzawa, Y. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0823-5 · Cited by 191 · see citing works

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

Ishibashi, S., Arai, H., Yokote, K., Araki, E., Suganami, H., & Yamashita, S. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.10.006 · Cited by 184 · see citing works

Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

Araki, E., Yamashita, S., Arai, H., Yokote, K., Satoh, J., Inoguchi, T., Nakamura, J., Maegawa, H., Yoshioka, N., Tanizawa, Y., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1589 · Cited by 164 · see citing works

Mechanism of homocysteine-mediated endothelial injury and its consequences for atherosclerosis

Yuan, D., Chu, J., Lin, H., Zhu, G., Qian, J., Yu, Y., Yao, T., Ping, F., Chen, F., & Liu, X. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1109445 · Cited by 152 · see citing works

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0864-7 · Cited by 140 · see citing works

Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease

Fougerat, A., Montagner, A., Loiseau, N., Guillou, H., & Wahli, W. (2020) · Cells · doi:10.3390/cells9071638 · Cited by 147 · see citing works

Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia

Fruchart, J.-C. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0602-y · Cited by 141 · see citing works

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial

Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., Ishibashi, S., & on behalf of the K-877 Study Group (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.44412 · Cited by 136 · see citing works

Perfluorooctanoic acid activates multiple nuclear receptor pathways and skews expression of genes regulating cholesterol homeostasis in liver of humanized PPARα mice fed an American diet

Schlezinger, J. J., Puckett, H. M., Oliver, J., Nielsen, G. H., Heiger‐Bernays, W., & Webster, T. F. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115204 · Cited by 119 · see citing works

Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content

Sasaki, Y., Asahiyama, M., Tanaka, T., Yamamoto, S., Murakami, K., Kamiya, W., Matsumura, Y., Osawa, T., Anai, M., Fruchart, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-64902-8 · Cited by 110 · see citing works

PPARs and Mitochondrial Metabolism: From NAFLD to HCC

Mello, T., Materozzi, M., & Galli, A. (2016) · PPAR Research · doi:10.1155/2016/7403230 · Cited by 92 · see citing works

PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients

Lange, N. F., Graf, V., Caussy, C., & Dufour, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084305 · Cited by 81 · see citing works

The PPAR–microbiota–metabolic organ trilogy to fine‐tune physiology

Oh, H. Y. P., Visvalingam, V., & Wahli, W. (2019) · The FASEB Journal · doi:10.1096/fj.201802681rr · Cited by 78 · see citing works

The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice

Araki, M., Nakagawa, Y., Oishi, A., Han, S., Wang, Y., Kumagai, K., Ohno, H., Mizunoe, Y., IWASAKI, H. O., Sekiya, M., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072148 · Cited by 79 · see citing works

Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases

Yamashita, S., Masuda, D., & Matsuzawa, Y. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.48918 · Cited by 68 · see citing works

Pemafibrate: First Global Approval

Blair, H. A. (2017) · Drugs · doi:10.1007/s40265-017-0818-x · Cited by 54 · see citing works

PPAR-α agonists are still on the rise: an update on clinical and experimental findings

Ferri, N., Corsini, A., Sirtori, C. R., & Ruscica, M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1312339 · Cited by 56 · see citing works

Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα

Yamamoto, Y., Takei, K., Arulmozhiraja, S., Sládek, V., Matsuo, N., Han, S., Matsuzaka, T., Sekiya, M., Tokiwa, T., Shoji, M., et al. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.135 · Cited by 53 · see citing works

Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia

Yamashita, S., Arai, H., Yokote, K., Araki, E., Suganami, H., & Ishibashi, S. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.06.010 · Cited by 51 · see citing works

International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily—Update 2023

Burris, T. P., de Vera, I. M. S., Côté, I., Flaveny, C. A., Wanninayake, U. S., Chatterjee, A., Walker, J. K., Steinauer, N., Zhang, J., Coons, L. A., et al. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000436 · Cited by 53 · see citing works

Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination

Yamashita, S., Arai, H., Yokote, K., Araki, E., Matsushita, M., Nojima, T., Suganami, H., & Ishibashi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225537 · Cited by 48 · see citing works

Pemafibrate Prevents Retinal Pathological Neovascularization by Increasing FGF21 Level in a Murine Oxygen-Induced Retinopathy Model

Tomita, Y., Ozawa, N., Miwa, Y., Ishida, A., Ohta, M., Tsubota, K., & Kurihara, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235878 · Cited by 49 · see citing works

Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52‐week data from the PROVIDE study

Araki, E., Yamashita, S., Arai, H., Yokote, K., Satoh, J., Inoguchi, T., Nakamura, J., Maegawa, H., Yoshioka, N., Tanizawa, Y., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13686 · Cited by 46 · see citing works

A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice

Sairyo, M., Kobayashi, T., Masuda, D., Kanno, K., Zhu, Y., Okada, T., Koseki, M., Ohama, T., Nishida, M., Sakata, Y., et al. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.39693 · Cited by 52 · see citing works

Pemafibrate Protects Against Retinal Dysfunction in a Murine Model of Diabetic Retinopathy

Tomita, Y., Lee, D., Miwa, Y., Jiang, X., Ohta, M., Tsubota, K., & Kurihara, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176243 · Cited by 46 · see citing works

Renoprotective effect of a novel selective PPARα modulator K-877 in db/db mice: A role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway

Maki, T., Maeda, Y., Sonoda, N., Makimura, H., Kimura, S., Maeno, S., Takayanagi, R., & Inoguchi, T. (2017) · Metabolism · doi:10.1016/j.metabol.2017.02.013 · Cited by 44 · see citing works

Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials

Yokote, K., Yamashita, S., Arai, H., Araki, E., Matsushita, M., Nojima, T., Suganami, H., & Ishibashi, S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01291-w · Cited by 45 · see citing works

Selective peroxisome proliferator‐activated receptor‐α modulator K‐877 efficiently activates the peroxisome proliferator‐activated receptor‐α pathway and improves lipid metabolism in mice

Takei, K., Han, S., Murayama, Y., Satoh, A., Oikawa, F., Ohno, H., Osaki, Y., Matsuzaka, T., Sekiya, M., IWASAKI, H. O., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12621 · Cited by 44 · see citing works

Effects of a novel selective peroxisome proliferator‐activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance

Matsuba, I., Matsuba, R., Ishibashi, S., Yamashita, S., Arai, H., Yokote, K., Suganami, H., & Araki, E. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12845 · Cited by 44 · see citing works

Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice

Takei, K., Nakagawa, Y., Wang, Y., Han, S.-I., Satoh, A., Sekiya, M., Matsuzaka, T., & Shimano, H. (2017) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2017.02.003 · Cited by 43 · see citing works

PPARα Agonist Oral Therapy in Diabetic Retinopathy

Tomita, Y., Lee, D., Tsubota, K., & Kurihara, T. (2020) · Biomedicines · doi:10.3390/biomedicines8100433 · Cited by 42 · see citing works

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis

Yamashita, S., Rizzo, M., Su, T., & Masuda, D. (2023) · Metabolites · doi:10.3390/metabo13050626 · Cited by 40 · see citing works

Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate

Sasaki, Y., Raza-Iqbal, S., Tanaka, T., Murakami, K., Anai, M., Osawa, T., Matsumura, Y., Sakai, J., & Kodama, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225682 · Cited by 38 · see citing works

Recent advances in synthetic pharmacotherapies for dyslipidaemias

Sirtori, C. R., Yamashita, S., Greco, M. F., Corsini, A., Watts, G. F., & Ruscica, M. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319845314 · Cited by 34 · see citing works

Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis

Murakami, K., Sasaki, Y., Asahiyama, M., Yano, W., Takizawa, T., Kamiya, W., Matsumura, Y., Anai, M., Osawa, T., Fruchart, J., et al. (2022) · Cells · doi:10.3390/cells11040720 · Cited by 34 · see citing works

In vivo interactions between α7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α: Implication for nicotine dependence

Jackson, A. B., Bağdaş, D., Muldoon, P. P., Lichtman, A. H., Carroll, F. I., Greenwald, M. K., Miles, M. F., & Damaj, M. I. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.03.005 · Cited by 33 · see citing works

Exposure of female mice to perfluorooctanoic acid suppresses hypothalamic kisspeptin‐reproductive endocrine system through enhanced hepatic fibroblast growth factor 21 synthesis, leading to ovulation failure and prolonged dioestrus

Zhang, Y., Cao, X., Chen, L., Qin, Y., Xu, Y., Tian, Y., & Chen, L. (2020) · Journal of Neuroendocrinology · doi:10.1111/jne.12848 · Cited by 31 · see citing works

Pemafibrate, a selective PPARα modulator, and fenofibrate suppress microglial activation through distinct PPARα and SIRT1-dependent pathways

Ogawa, K., Yagi, T., Guo, T., Takeda, K., Ohguchi, H., Koyama, H., Aotani, D., Imaeda, K., Kataoka, H., & Tanaka, T. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.01.118 · Cited by 31 · see citing works

PPARα activation directly upregulates thrombomodulin in the diabetic retina

Shiono, A., Sasaki, H., Sekine, R., Abe, Y., Matsumura, Y., Inagaki, T., Tanaka, T., Kodama, T., Aburatani, H., Sakai, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-67579-1 · Cited by 31 · see citing works

Overexpression of p54nrb/NONO induces differentialEPHA6splicing and contributes to castration-resistant prostate cancer growth

Yamamoto, R., Osawa, T., Sasaki, Y., Yamamoto, S., Anai, M., Izumi, K., Matsumura, Y., Sakai, J., Aburatani, H., Mizokami, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24063 · Cited by 30 · see citing works

Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?

Fruchart, J., Hermans, M. P., Fruchart‐Najib, J., & Kodama, T. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00897-x · Cited by 29 · see citing works

Sex-regulated gene dosage effect of PPARα on synaptic plasticity

Pierrot, N., Ris, L., Stancu, I., Doshina, A., Ribeiro, F., Tyteca, D., Baugé, E., Lalloyer, F., Malong, L., Schakman, O., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201800262 · Cited by 27 · see citing works

Hypertriglyceridemia Therapy: Past, Present and Future Perspectives

Canfora, I., & Pierno, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179727 · Cited by 27 · see citing works

Elucidation of Molecular Mechanism of a Selective PPARα Modulator, Pemafibrate, through Combinational Approaches of X-ray Crystallography, Thermodynamic Analysis, and First-Principle Calculations

Kawasaki, M., Kambe, A., Yamamoto, Y., Arulmozhiraja, S., Ito, S., Nakagawa, Y., Tokiwa, H., Nakano, S., & Shimano, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21010361 · Cited by 26 · see citing works

Pemafibrate Prevents Retinal Dysfunction in a Mouse Model of Unilateral Common Carotid Artery Occlusion

Lee, D., Tomita, Y., Jeong, H., Miwa, Y., Tsubota, K., Negishi, K., & Kurihara, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179408 · Cited by 23 · see citing works

Future Directions in Diabetic Retinopathy Treatment: Stem Cell Therapy, Nanotechnology, and PPARα Modulation

Kąpa, M., Koryciarz, I., Kustosik, N., Jurowski, P., & Pniakowska, Z. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030683 · Cited by 22 · see citing works

Identification of Picrasidine C as a Subtype-Selective PPARα Agonist

Zhao, S., Kanno, Y., Li, W., Sasaki, T., Zhang, X., Wang, J., Cheng, M., Koike, K., Nemoto, K., & Li, H. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.6b00883 · Cited by 22 · see citing works

Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis

Mahmoudi, A. A., Butler, A. E., Jamialahmadi, T., & Sahebkar, A. (2021) · BioMed Research International · doi:10.1155/2021/3654660 · Cited by 20 · see citing works

Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice

Zhang, Z., Diao, P., Zhang, X., Nakajima, T., Kimura, T., & Tanaka, N. (2022) · Biomedicines · doi:10.3390/biomedicines10071667 · Cited by 20 · see citing works

Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?

Fruchart, J., Hermans, M. P., & Fruchart‐Najib, J. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00860-w · Cited by 18 · see citing works

Pemafibrate Protects against Fatty Acid-Induced Nephropathy by Maintaining Renal Fatty Acid Metabolism

Aomura, D., Harada, M., Yamada, Y., Nakajima, T., Hashimoto, K., Tanaka, N., & Kamijo, Y. (2021) · Metabolites · doi:10.3390/metabo11060372 · Cited by 20 · see citing works

PPARα Modulation-Based Therapy in Central Nervous System Diseases

Lee, D., Tomita, Y., Allen, W., Tsubota, K., Negishi, K., & Kurihara, T. (2021) · Life · doi:10.3390/life11111168 · Cited by 17 · see citing works

Selective peroxisome proliferator-activated receptor-α modulator K-877 regulates the expression of ATP-binding cassette transporter A1 in pancreatic beta cells

Dong, T., Lyu, J., Imachi, H., Kobayashi, T., Fukunaga, K., Sato, S., Ibata, T., Yoshimoto, T., Yonezaki, K., Iwama, H., et al. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.09.015 · Cited by 15 · see citing works

Small-Molecule Modulation of PPARs for the Treatment of Prevalent Vascular Retinal Diseases

Dou, X., & Duerfeldt, A. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239251 · Cited by 14 · see citing works

Different Coactivator Recruitment to Human PPARα/δ/γ Ligand-Binding Domains by Eight PPAR Agonists to Treat Nonalcoholic Fatty Liver Disease

Kamata, S., Honda, A., Kashiwagi, N., Shimamura, A., Yashiro, S., Komori, Y., Hosoda, A., Akahoshi, N., & Ishii, I. (2024) · Biomedicines · doi:10.3390/biomedicines12030624 · Cited by 14 · see citing works

Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.5 · Cited by 15 · see citing works

Regulation of the expression of cholesterol transporters by lipid-lowering drugs ezetimibe and pemafibrate in rat liver and intestine

Tanaka, Y., & Kamisako, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166215 · Cited by 14 · see citing works

Recent developments in pharmacotherapy for hypertriglyceridemia: what’s the current state of the art?

Florentin, M., Kostapanos, M. S., Anagnostis, P. G., & Liamis, G. L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691523 · Cited by 14 · see citing works

Discovery of peroxisome proliferator–activated receptor α (PPARα) activators with a ligand-screening system using a human PPARα-expressing cell line

Tachibana, K., Yuzuriha, T., Tabata, R., Fukuda, S., Maegawa, T., Takahashi, R., Tanimoto, K., Tsujino, H., Nunomura, K., Lin, B., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002077 · Cited by 13 · see citing works

Pharmacokinetics and metabolism of pemafibrate, a novel selective peroxisome proliferator‐activated receptor‐ <b>alpha</b> modulator, in rats and monkeys

Ogawa, S., Tsunenari, Y., Kawai, H., & Yamazaki, H. (2019) · Biopharmaceutics &amp; Drug Disposition · doi:10.1002/bdd.2165 · Cited by 12 · see citing works

Impact of pemafibrate in patients with metabolic dysfunction‐associated steatotic liver disease complicated by dyslipidemia: A single‐arm prospective study

Ono, H., Atsukawa, M., Tsubota, A., Arai, T., Suzuki, K. M., Higashi, T., Kitamura, M., Shioda, K., Kawano, T., Yoshida, Y., et al. (2024) · JGH Open · doi:10.1002/jgh3.13057 · Cited by 14 · see citing works

PPARα regulates the expression of human arylacetamide deacetylase involved in drug hydrolysis and lipid metabolism

Morikawa, T., Fukami, T., Gotoh, S., Nakano, M., & Nakajima, M. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115010 · Cited by 12 · see citing works

Tanshinol A Ameliorates Triton‐1339W‐Induced Hyperlipidemia and Liver Injury in C57BL/6J Mice by Regulating mRNA Expression of Lipemic‐Oxidative Injury Genes

Li, Y., Yuxing, C., Huang, X., Huang, D., Gan, H., Yao, N., Hu, Z., Li, R., Zhan, X., Xie, K., et al. (2020) · Lipids · doi:10.1002/lipd.12217 · Cited by 12 · see citing works

Structural development of 1H-pyrazolo-[3,4-b]pyridine-4-carboxylic acid derivatives as human peroxisome proliferator-activated receptor alpha (PPARα)-selective agonists

Miyachi, H., Yuzuriha, T., Tabata, R., Fukuda, S., Nunomura, K., Lin, B., Kobayashi, T., Ishimoto, K., Doi, T., & Tachibana, K. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.06.062 · Cited by 11 · see citing works

Pemafibrate abrogates SLD in a rat experimental dietary model, inducing a shift in fecal bile acids and microbiota composition

Bentanachs, R., Miró, L., Sánchez, R. M., Ramírez-Carrasco, P., Amat, C., Alegret, M., Pérez, A., Roglans, N., & Laguna, J. C. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117067 · Cited by 10 · see citing works

Efficacy and Safety of Pemafibrate, a Novel Selective PPARα Modulator in Chinese Patients with Dyslipidemia: A Double-Masked, Randomized, Placebo- and Active-Controlled Comparison Trial

Dai, W., Lv, Q., Li, Q., Fu, L., Zhang, Y., Zhang, Y., Liu, L., Tanigawa, R., Kunitomi, K., Kamei, R., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64112 · Cited by 10 · see citing works

Higher Responsiveness for Women, High Transaminase Levels, and Fat Percentage to Pemafibrate Treatment for NAFLD

Iwadare, T., Kimura, T., Kunimoto, H., Tanaka, N., Wakabayashi, S., Yamazaki, T., Okumura, T., Kobayashi, H., Yamashita, Y., Sugiura, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10112806 · Cited by 10 · see citing works

Pemafibrate Tends to have Better Efficacy in Treating Dyslipidemia than Fenofibrate

Wang, H., Li, H., Zhou, Y., Liu, J., Wang, F., & Zhao, Q. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612825666191126102943 · Cited by 11 · see citing works

Management of Mild-to-Moderate Hypertriglyceridemia

Pulipati, V. P., Brinton, E. A., & Hatipoğlu, B. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.07.003 · Cited by 9 · see citing works

Contemporary and Novel Therapeutic Options for Hypertriglyceridemia

Bell, D. A., & Watts, G. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.08.001 · Cited by 9 · see citing works

Pemafibrate Prevents Rupture of Angiotensin II-Induced Abdominal Aortic Aneurysms

Amioka, N., Miyoshi, T., Yonezawa, T., Kondo, M., Akagi, S., Yoshida, M., Saito, Y., Nakamura, K., & Ito, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.904215 · Cited by 9 · see citing works

Integrative Multiomics Approaches for Discovery of New Drug Targets for Cardiovascular Disease

Reilly, M. P., & Bornfeldt, K. (2021) · Circulation · doi:10.1161/circulationaha.121.054900 · Cited by 8 · see citing works

Prediction of circulating human metabolites of pemafibrate, a novel antidyslipidemic drug, using chimeric mice with humanized liver

Ogawa, S.-I., Uehara, S., Tsunenari, Y., Kawai, H., Suemizu, H., & Yamazaki, H. (2019) · Xenobiotica · doi:10.1080/00498254.2019.1694198 · Cited by 6 · see citing works

Differentially Expressed Genes in Response to a Squalene-Supplemented Diet Are Accurate Discriminants of Porcine Non-Alcoholic Steatohepatitis

Abuobeid, R., Herrera-Marcos, L. V., Arnal, C., Bidooki, S. H., Sánchez-Marco, J., Lasheras, R., Surra, J. C., Rodriguez‐Yoldi, M. J., Martínez‐Beamonte, R., & Osada, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612552 · Cited by 6 · see citing works

Fibrates: A Possible Treatment Option for Patients with Abdominal Aortic Aneurysm?

Amioka, N., & Miyoshi, T. (2022) · Biomolecules · doi:10.3390/biom12010074 · Cited by 6 · see citing works

Long-Term pemafibrate treatment exhibits limited impact on body fat mass in patients with hypertriglyceridemia accompanying NAFLD

Iwadare, T., Kimura, T., Kunimoto, H., Okumura, T., Wakabayashi, S., Kobayashi, H., Yamashita, Y., Sugiura, A., Tanaka, N., & Umemura, T. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1329294 · Cited by 5 · see citing works

Fibrates : Do They Still Have a Role in Therapy in 2025?

Pirillo, A., Zambon, A., & Catapano, A. L. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01379-8 · Cited by 4 · see citing works

Treatment of Hypertriglyceridemia: A Review of Therapies in the Pipeline

Xu, J., & Ashjian, E. J. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211053489 · Cited by 4 · see citing works

Calorie Restriction Using High-Fat/Low-Carbohydrate Diet Suppresses Liver Fat Accumulation and Pancreatic Beta-Cell Dedifferentiation in Obese Diabetic Mice

Lei, X., Ishida, E., Yoshino, S., Matsumoto, S., Horiguchi, K., & Yamada, E. (2024) · Nutrients · doi:10.3390/nu16070995 · Cited by 5 · see citing works

Investigational drugs in development for hypertriglyceridemia: a coming-of-age story

Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4 · see citing works

New and Emerging Therapies for Dyslipidemia

Zambon, A., Averna, M. R., D’Erasmo, L., Arca, M., & Catapano, A. L. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.004 · Cited by 4 · see citing works

Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model

Kimura, A., Kamimura, K., Ohkoshi-Yamada, M., Shinagawa‐Kobayashi, Y., Goto, R., Owaki, T., Oda, C., Shibata, O., Morita, S., Sakai, N., et al. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.01.086 · Cited by 4 · see citing works

Combination therapy with clinically approved PPARα/δ/γ subtype-selective agonists pemafibrate, seladelpar, and pioglitazone in a 4-week diet-induced early-stage MASLD mouse model

Honda, A., Kamata, S., Tanaka, R., Minomo, Y., Ino, S., Kamichatani, W., Hishiki, T., Akahoshi, N., Nakagawa, S., Nunomura, K., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119432 · Cited by 3 · see citing works

Pemafibrate Induces a Low Level of PPARα Agonist-Stimulated mRNA Expression of ANGPTL4 in ARPE19 Cell

Ohguro, H., Nishikiori, N., Sato, T., Watanabe, M., Higashide, M., & Furuhashi, M. (2024) · Bioengineering · doi:10.3390/bioengineering11121247 · Cited by 3 · see citing works

Protective Effect of Pemafibrate Treatment against Diabetic Retinopathy in Spontaneously Diabetic Torii Fatty Rats

Tanaka, Y., Takagi, R., Mitou, S., Shimmura, M., Hasegawa, T., Amarume, J., Shinohara, M., Kageyama, Y., Sasase, T., Ohta, T., et al. (2024) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b23-00872 · Cited by 3 · see citing works

Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion

Kitamura, S., Murao, N., Yokota, S., Shimizu, M., Ono, T., Seino, Y., Suzuki, A., Maejima, Y., & Shimomura, K. (2023) · BMC Research Notes · doi:10.1186/s13104-023-06489-7 · Cited by 2 · see citing works

Analysis of serum levels and DNA methylation of fibroblast growth factor 21 using peripheral blood-derived genomes in patients with obesity

Shinozaki, H., Kawai, S., Gamo-Kawasaki, M., Takei, A., Tsujikado, K., Fukuda, K., Yamauchi, M., Hara, K., Tsuchiya, T., Takebayashi, K., et al. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej23-0570 · Cited by 2 · see citing works

Effects of angiotensin receptor-neprilysin inhibitor on ketone body metabolism in pre-heart failure/heart failure patients

Kashiwagi, Y., Nagoshi, T., Tanaka, Y., Oi, Y., Kimura, H., Ogawa, K., Kawai, M., & Yoshimura, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-67524-6 · Cited by 1 · see citing works

Therapies Targeting HDLc Levels and HDL Function

Vitali, C., & Cuchel, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812513-7.00012-4 · Cited by 1 · see citing works

A Novel Selective PPARα Modulator

Doi, T. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed020

Lipid Management for Prevention of Atherosclerotic Cardiovascular Diseases

Yamashita, S. (2018) · Health Evaluation and Promotion · doi:10.7143/jhep.45.755

2. Pathophysiology of Atherosclerosis and Its Prevention and Treatment

Yamashita, S. (2019) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.108.1685

Elucidating the Efficacy of Clinical Drugs Using FMO

Arulmozhiraja, S., Tokiwa, H., & Shimano, H. (2021) · Springer eBooks · doi:10.1007/978-981-15-9235-5_16

Pemafibrate

Pulipati, V. P., & Brinton, E. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00023-6

Clinical Application of Blood Flow Reserve Fraction and Blood Homocysteine in Coronary Atherosclerotic Heart Disease

尔哈巴·阿卜力克木, 麦. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1441346

Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.69

Selective PPAR-α activation with pemafibrate attenuates macrophage-mediated progression of calcific aortic valve diseasePreprint

Turner, M. E., Nakamura, Y., Tanaka, T., Blaser, M. C., Kasai, T., Lupieri, A., Itoh, S., Ge, R., Perez, K. A., Itagawa, R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.17.694919

Beyond lipid-lowering effects: Challenges and insights in fenofibrate repurposing for oncology

Peng, L., Zhu, N., Zhang, C., Long, J.-P., Shi, Y., Yang, Q., Gong, Y.-Z., & Li, Q. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124541

Selective peroxisome proliferator‐activated receptor‐α modulator K‐877 efficiently activates the peroxisome proliferator‐activated receptor‐α pathway and improves lipid metabolism in mice

Takei, K., Han, S., Murayama, Y., Satoh, A., Oikawa, F., Ohno, H., Osaki, Y., Matsuzaka, T., Sekiya, M., IWASAKI, H. O., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12621 · Cited by 44 · see citing works

Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate

Sasaki, Y., Raza-Iqbal, S., Tanaka, T., Murakami, K., Anai, M., Osawa, T., Matsumura, Y., Sakai, J., & Kodama, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225682 · Cited by 38 · see citing works

The whole transcriptome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice

Rodriguez, M. A. D. L. R., Sugahara, G., Hooiveld, G. J. E. J., Ishida, Y., Tateno, C., & Kersten, S. (2018) · BMC Genomics · doi:10.1186/s12864-018-4834-3 · Cited by 52 · see citing works

新規選択的PPARα modulator（SPPARMα） K-877の非アルコール性肝炎モデルマウスに対する作用の検討

裕輔, 佐., 田中, 十., 壮登, 朝., 池田, 毅, 稲., 寿郎, 酒., & Kodama, T. (2016) · 特定非営利活動法人 日本分子生物学会

PPARα-dependent effects in the liver and jejunum of mice in response to pemafibratePreprint

Lasserre, F., Polizzi, A., Fougerat, A., Ellero‐Simatos, S., Lippi, Y., Huillet, M., Céline, M., Smati, S., Naylies, C., Garcia, G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.30.755633